



**1<sup>st</sup> International forum on prospective in cancer research and treatment  
2010, November 5-6, Paris**

**Museum National d'Histoire Naturelle, 57 rue Cuvier, 75005 PARIS**

<p><b>1st Day Friday, November 5, 2010 09:00 &gt; 18:00</b></p>	<p><i>8:30 Registration and welcome coffee</i></p>
	<p><b>Cancer situation: Prospective and challenges</b> 9:00 – 9:15 (TBC)</p> <p><b>Session 1: Alterations in cancer cell metabolism as new therapeutics targets</b> (session chaired by Jacques Pouyssegur)</p> <p>9:15 – 9:55 <b>Jacques Pouyssegur</b> (Centre A. Lacassagne, Nice)</p> <p>10:00 – 10:40 <b>Amato Giaccia</b> (Stanford University)</p> <p>10:45 – 11:20 Host energy balance and the functional status of the LKB1-AMPK energy sensor system identify cancers sensitive to metformin and similar agents <b>Michael Pollak</b> (McGill University)</p> <p>11:25 – 11:55 <b>Christoph Lengauer</b> (Sanofi Aventis)</p> <p>12:00 – 13:00 Round table and discussion: what is next?</p>
<p><i>13:00 – 14:15 Lunch provided at Restaurant "La Baleine"</i></p>	<p><b>Session 2: Ten years after the first kinases inhibitors: what perspectives in terms of cancer treatment ?</b> (session chaired by Sir Philip Cohen)</p> <p>14:15 – 15:00 Protein kinases as targets for the development of anti-cancer drugs <b>Sir Philip Cohen</b> (University of Dundee)</p> <p>15:05 – 15:50 <b>Joseph Schlessinger</b> (Yale University)</p> <p>15:55 – 16:25 <b>Jean Charles Soria</b> (Institut Gustave Roussy)</p> <p>16:30 – 17:00 PI3K pathway inhibition in cancer <b>Bart Vanhaesebroeck</b> (Institute of cancer, QMUL, London)</p> <p>17:00 – 18:00 Round table and discussion: what is next?</p>
<p><b>18:30 Cocktail</b></p>	

<p style="text-align: center;"><b>2nd Day</b> <b>Saturday, November 6,</b> <b>2010</b> <b>09:00 &gt; 18:00</b></p>	<i>8:30 Registration and welcome coffee</i>
	<p>9:00 -9:30 <b>Elio Riboli</b> (Imperial College)</p> <p><b>Session 3: Cancer stem cells, even more attractive targets</b> (session chaired by Robert Weinberg)</p> <p>9:30 – 10:15 Malignant Progression and Cancer Stem Cells <b>Robert Weinberg</b> (Whitehead Institute, Cambridge)</p> <p>10:15 – 10:45 Cells and genes in breast cancer <b>Daniel Birnbaum</b> (Institut Paoli Calmettes, Marseille)</p> <p>10:50 – 11:30 <b>Peter Dirks</b> (University of Toronto)</p> <p>11:30 – 12:15 <b>Michael Clarke</b> (Stanford University)</p> <p>12:20 – 13:20 Round table and discussion: what is next?</p>
<p><i>13:30 – 14:30 Lunch provided at Restaurant "La Baleine"</i></p>	<p><b>Session 4: Monoclonal antibodies, therapeutic tools with growing efficacy</b></p> <p>14:30 – 15:15 Combination therapies (TBC)</p> <p>15:20 – 15:55 Biomarkers for selection of targeted therapy <b>Pierre Laurent-Puig</b> (Université Paris 5)</p> <p>15:55 – 16:25 How post translational modifications of antibodies affect their activity <b>Pablo Umana</b> (Roche Glycart)</p> <p>16:30 – 17:30 Round table and discussion: what is next?</p>
	<p>17:30-17:45 Concluding remarks</p>